With nearly 20% of its landmass expected to be underwater by mid-century, Bangladesh is one of the most climate-vulnerable countries on Earth. But new buildings and public spaces across the capital city of Dhaka are (sometimes literally) rising to meet the challenges of a hotter, wetter future. Brac University’s new campus, seen here, opened in central Dhaka in 2024
NEWBURY, England, July 7, 2025 /PRNewswire/ — Osteotec, the market leading manufacturer and distributor of specialised medical devices, is pleased to announce it has entered into an exclusive UK distribution agreement with pioneer German spine technology manufacturer Ulrich Medical.
This strategic partnership, effective from July 1, 2025, reinforces Osteotec’s growing spine offering and expands access to Ulrich Medical’s advanced vertebral body replacement systems, systems for cervical and thoraco-lumbar fusion, and dynamic spinal stabilisation solutions across the UK.
The agreement represents a strategic alignment between two companies committed to enhancing surgical performance and delivering better outcomes for patients requiring complex spinal interventions, providing Ulrich Medical’s world-renowned implant systems for cervical, thoracic and lumbar applications to surgeons throughout the NHS and private healthcare sectors.
Founded in 1912 and headquartered in Ulm, Germany, Ulrich Medical has earned a global reputation for precision-engineered solutions that combine robust design, biomechanical innovation, and high standards of German manufacturing. Operating in more than 70 markets worldwide, the company is recognised for its pioneering work in expandable vertebral body replacement implants and dynamic systems that restore anatomical alignment while preserving motion and stability.
The addition of Ulrich Medical’s comprehensive spinal portfolio complements Osteotec’s mission to support spine specialists with reliable, clinically proven technologies that meet the demands of modern spine surgery.
“Our collaboration with Ulrich Medical marks a significant addition to our spine portfolio,” said Dean Stockwell, Osteotec Sales and Marketing Director.
“Ulrich’s focus on restoring spinal function through engineering excellence perfectly aligns with our commitment to offering UK surgeons high-performance, thoughtfully designed implant systems. This agreement allows us to broaden the choice of solutions available to surgeons and improve outcomes for patients undergoing spinal reconstruction.”
Ulrich Medical’s systems are widely trusted by spinal surgeons across Europe, the USA and beyond for their intuitive handling and predictable clinical performance. The partnership with Osteotec ensures these technologies will now be readily accessible to the UK spine surgery community through a trusted domestic distributor with more than three decades of expertise.
“We are pleased to partner with Osteotec, a company with a strong presence and reputation in the UK surgical market,” said Cornelia Schweizer, Vice President Global Sales and Marketing at Ulrich Medical. “Our shared values of quality, innovation and surgeon-focused support will help deliver our technologies to a wider audience and ultimately, support the delivery of best possible patient care.”
About Osteotec
Osteotec is a manufacturer and distributor of medical devices headquartered in Newbury, UK, with offices in Dublin and Malmö. Established in 1993, Osteotec has been supplying into the NHS and private healthcare sectors for the past 32 years.
Osteotec manufactures and distributes the Osteotec Silicone Finger, ChiroKlip and the Concentric Bone Graft System and is a distributor for world-leading orthopaedic partners including Highridge Medical, SI-BONE, TriMed, Enovis, Novastep and Cerapedics.
Media Contact: Harriet Bawden Marketing Manager [email protected] | 020 3011 5574 For more information, visit – www.osteotec.com
About Ulrich Medical
The ulrich medical group consists of the mother company ulrich GmbH & Co. KG and its subsidiaries in France, Spain and the USA. The internationally operating group develops, produces and distributes products for spinal surgery and radiology under the ulrich medical brand. Founded in 1912, the family-owned company employs over 650 people worldwide. While the products are used worldwide, the medical technology company focuses on quality “Made in Germany“, where the majority of development and production takes place. An additional development site in the USA creates proximity to the international markets for the innovative solutions. ulrich medical increased its turnover again in 2024 – for the 15th year in a row – and underlines its position as a reliable partner in the medical technology industry with this sustained growth.
Media Contact: Isabelle Korger Manager PR & Corporate Communications [email protected] | +49 (0)731 9654-103 For more information, visit – www.ulrichmedical.com
After four years of development and $25 million invested, Revolving Games’ latest title, War of Nova, has quickly emerged as one of the fastest-growing strategy games in its category. The real-time 4X strategy MMORPG is:
Tracking toward $30 million in annualized revenue
Seeing 40% that revenue generated by players on App Store and Google Play
Showing strong player retention and engagement with D1/D3/D7 retention rates of 45/38/26, respectively and 30 minute average session lengths
Launching Season 2 with improved social features in August
In parallel, HatchKings, Revolving Games’ social slots game, set a new on-chain gaming revenue record by generating $1.4 million in just 10 days, outperforming previous benchmarks set by leading Web3 games.
These numbers are more than just proof points. They signal what many have questioned – that Web3 games can, in fact, break into the mainstream. With nearly half of War of Nova’s revenue coming from everyday mobile players, Revolving Games is closing the gap between traditional mobile gaming and next-generation, player-powered infrastructure.
A Growing Player Community and Publisher Ecosystem
With four launched games, a robust live service operation, and a loyal player base investing into its infrastructure, Revolving Games is laying the groundwork for a scalable, player-first publishing platform. The company’s upcoming roadmap includes:
The launch of Skyborne: Phoenix Flight, a casual invest-express RPG reminiscent of Animal Crossing, set to debut in Limited Access later this year
Continued updates and seasonal content for War of Nova, HatchKings, and Hatchlings
Onboarding IP Partners into the Publisher Ecosystem
The rollout of the RCADE Network, a player-powered infrastructure layer designed to connect games, studios, and players through real rewards and shared growth
“With the traction we’re seeing across our live games and Skyborne: Phoenix Flight on deck, we believe Revolving Games is positioned to reach $60 million in ARR by the end of the year,” added Ammar Zaeem, Co-Founder and Co-CEO of Revolving Games. “It’s a reflection of years of quiet work and our belief that building for real players — not hype — is what drives long-term growth.”
Building for the Long Term
Backed by industry giants Pantera Capital, Animoca Brands, Polygon, and Rockstar Games’ co-creator Dan Houser, Revolving Games has shown through its commercial success and rapid growth that it’s leading the way for next-gen gaming.
“Four years ago, we set out to build games that people actually want to play and it still remains the mission,” said Saad Zaeem, Co-Founder and Co-CEO of Revolving Games. “Seeing War of Nova and HatchKings take off proves that when you focus on gameplay and community first, everything else follows.”
Revolving Games has been recognized as #27 Forbes’ Best Startup Employers and Newsweek’s Greatest Startup Workplaces in 2025. The company continues to scale globally with studios in North America, Europe, and Asia.
About Revolving Games
Revolving Games is a global game developer and decentralized publisher creating scalable, player-owned gaming experiences through high-quality gameplay and connected infrastructure. With teams across North America, Europe, and Asia, the company has launched multiple titles spanning strategy, social simulation, and RPG genres.
Backed by prominent investors including Pantera Capital, Animoca Brands, Polygon, Dapper Labs, Permanens Capital Partners, and others, Revolving Games is setting new standards for what’s possible in Web3 gaming, and has been recognized by Forbes and Newsweek as one of America’s Best Startup Employers (https://www.forbes.com/lists/americas-best-startup-employers/) and Greatest Startup Workplaces (https://rankings.newsweek.com/americas-greatest-startup-workplaces-2025) in 2025.
Revolving Games is dedicated to building decentralized, long-lasting, and seriously fun games that rival the best of traditional AAA gaming. For more information, users can visit:
WASHINGTON and LEXINGTON PARK, Md., July 7, 2025 /PRNewswire/ — Saalex Corporation, a leading provider of defense and technology solutions, today announced its acquisition of Greenfield Engineering Corporation. Greenfield is a premier software and systems engineering firm specializing in avionics software development for the U.S. Navy.
This strategic acquisition significantly enhances Saalex’s software development capabilities, particularly in highly specialized avionics software for complex real-time systems. Founded in 2002 and headquartered in Lexington Park, MD, Greenfield has established itself as a trusted partner to NAVAIR with expertise in embedded real-time software development, configuration management, and program management support for naval aviation platforms. The company’s 61 employees will join Saalex Corporation, with integration beginning immediately upon closing July 3, 2025.
“The acquisition of Greenfield Engineering demonstrates the Saalex Corporation commitment to supporting the warfighter and growing our software development capabilities in highly sensitive and secure DOD environments,” said Travis Mack, Chairman and CEO of Saalex Corporation. “I am extremely pleased to continue our expansion and growth in the Patuxent Maryland area.”
Will Weston, President and CEO of Greenfield Engineering, will remain with Saalex to ensure continuity of service excellence and support the integration process. “Joining Saalex Corporation represents an exciting opportunity for Greenfield Engineering to expand our capabilities while maintaining our commitment to supporting critical naval aviation programs,” said Weston. “This partnership will enable us to better serve our customers while providing growth opportunities for our team.”
The acquisition builds upon Saalex’s recent Spalding acquisition, creating a complementary presence in the Patuxent River area and establishing a strong foundation for continued growth in software development services. Greenfield’s specialized expertise in avionics software development, combined with its strong NAVAIR relationships and significant contract backlog, positions the combined organization for continued success in supporting critical defense programs.
About Saalex Corporation: Saalex Corporation is a leading Aerospace & Defense services company specializing in providing Test Range Operations, IT & cybersecurity, Engineering, Unmanned Robotic Process Automation (URPA), Software Development, and Training/Wargaming Support services to the Department of Defense. With a proven track record of delivering exceptional value and mission-driven solutions, Saalex has been a trusted partner to government agencies for over 25 years.
After a slow spring, investment firms of the ultra-rich made 60 direct investments in June, according to Fintrx.
Family offices flocked to biotech and health-care firms such as Antheia, seeking to make an impact and returns at the same time.
Antheia founder Christina Smolke told CNBC’s Inside Wealth family offices’ patient capital makes them a good fit for investing in scientific breakthroughs.
A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. For investment firms of the ultra-wealthy, deal-making is heating up. In June, family offices made 60 direct investments in companies, ending three straight months of declining deal activity, according to data provided exclusively to CNBC by Fintrx. June’s tally is an improvement over the 47 deals recorded in May , though it marks a 40% drop on a year-over-year basis, per the private wealth platform. June saw a few buzzy deals in entertainment. The investment firm for Nintendo’s founding family bought a minority stake in indie film studio K2 Pictures for an undisclosed amount. Yamauchi No. 10 Family Office is also investing in the startup’s film production fund, a Hollywood-esque financing strategy that is rare in Japan. Stateside, Blackstone billionaire David Blitzer joined a $20 million fundraise for Ballers, a members club for sports including padel and virtual golf. A slew of professional athletes, including tennis Hall of Famer Andre Agassi, also participated in the round. But biotech and health care proved to be more popular themes, accounting for nine deals by heavy-hitter family offices. Narcan ingredient maker Antheia raised a $56 million Series C with investors including family offices Athos KG and S-Cubed Capital. Athos KG’s principals, billionaire twins Andreas and Thomas Strüngmann, made their fortune with generic drugmaker Hexal and invested in Covid vaccine maker BioNTech . S-Cubed Capital is helmed by billionaire and former Sequoia partner Mark Stevens. Former Google CEO Eric Schmidt’s Hillspire has been an investor in Antheia since its $73 million Series B in 2021. Scientist-turned-entrepreneur Christina Smolke co-founded Antheia in 2015 after discovering how to bioengineer yeast to manufacture opioids for medical use in less than two weeks. Typically, the process of producing hydrocodone from opium poppies can take two years between farming, harvesting and extraction, Smolke said in an interview with CNBC. Smolke, a Stanford professor with a Ph.D. in chemical engineering, told Inside Wealth that family offices, which tend to invest with long investment horizons, are well suited for biotechnology investments. “These are complicated problems. There’s not a sort of a quick patch that we’re going to put on this,” she said. “Family offices tend to be able to be patient with their investments, and that aligns really well with the cycles and the timelines that are needed for biotech and to bring new products, new technology and new transformation, at a system level, to healthcare.” In late 2024, Antheia launched its first product, thebaine, a key ingredient in overdose reversal medication Narcan. The recent fundraise will allow Antheia to expand production from Europe to the U.S. and bring other products to market. The Menlo Park, California-based firm is developing 70-plus pharmaceutical ingredients necessary for medicines used to treat cancer, bacterial infections, seizures and other conditions. “The core aspect that’s shared through all of this is being able to rebuild these essential medicine supply chains so that drug shortages become a thing of the past and access, globally, becomes more equitable,” she said. For impact-driven family offices, biotechnology can serve as a familiar frontier, Smolke said. “It can speak to investors very directly,” she said. “I think everybody has actually directly experienced challenges with drug shortages — even in the U.S. — of going to the supermarket and having cold medicines out of stock or not being able to get certain antibiotics.”
German researchers have developed a new roll-to-roll production process to make lithium batteries safer with better energy density.
Fraunhofer FEP has developed this process for a new type of component for lithium-ion batteries called metal-on-polymer current collectors.
As electric vehicles become more common, these new collectors could play a key role in preventing lithium-ion battery fires by acting as an internal safety mechanism.
Project manager Claus Luber shows a sample of polymer film coated with aluminum using electron beam evaporation. Credit: Fraunhofer FEP, Finn Hoyer
Preventing thermal runaway
This innovative technology aims to address the inherent fire risk in traditional lithium-ion batteries, often caused by “thermal runaway” due to overcharging, component damage, or overheating.
EV battery fires are difficult to extinguish because the batteries aren’t a single unit.
Instead, it is made of many individual cells packed together. Like a thermal runaway, a fire starting in one cell from a chemical reaction quickly spreads its intense heat to neighboring cells until the entire battery pack is engulfed.
The new current collectors replace conventional metal foils with polymer films coated on both sides with thin layers of aluminum or copper.
This seemingly small change brings huge advantages. Firstly, it reduces the weight of the current collector, leading to higher energy density in the battery cell. More power, less bulk.
But even more importantly, it’s key for safety. If a short circuit occurs, the polymer substrate simply melts, instantly interrupting the current path.
This stops heat from building up, directly preventing that dangerous thermal runaway. It’s an integrated safety fuse inside a battery.
Fraunhofer FEP perfected a roll-to-roll process using electron beam evaporation to apply these metal coatings precisely.
“The challenge was to design the polymer films and the coating process in such a way that the thickness of the current collector could be comparable to that of current metal films and the metal layer could have optimum electrical conductivity,” said Claus Luber, technical project manager.
And they did!
Safer future batteries
The method deposited double-sided coatings of both copper and aluminum on polymer films, with each layer up to 1 µm thick.
For both metals, the process resulted in compact, wrinkle-free films, making them ideal for integration into battery production.
The proof is in the performance. These new metal-on-polymer current collectors were integrated into pouch cells by project partner TU Braunschweig.
“These cells were tested for their electrochemical properties and compared with conventional reference cells,” the researchers noted.
“In these tests, the cells with metal-on-polymer current collectors performed similarly to the reference cells in terms of performance and cycle stability at different charging and discharging rates,” the press release added.
The team stated that these new metal-on-polymer battery parts can be made on a larger scale using the new roll-to-roll method.
These new parts can help batteries hold more power for their size, meaning potentially longer-lasting phones or longer-range electric cars.
If a problem causes the battery to short-circuit, these new collectors are designed to prevent dangerous overheating and potential fires.
This development gives battery makers a solid foundation to develop the next generation of improved lithium-ion batteries.
Zeb J, Szekeres S, Takacs N, Kontschan J, Shams S, Ayaz S, et al. Genetic diversity, piroplasms and trypanosomes in Rhipicephalus microplus and Hyalomma anatolicum collected from cattle in northern Pakistan. Exp Appl Acarol. 2019;79:233–43.
Article
CAS
Google Scholar
Truc P, Buscher P, Cuny G, Gonzatti MI, Jannin J, Joshi P, et al. Atypical human infections by animal trypanosomes. PLoS Negl Trop Dis. 2013;7: e2256.
Article
Google Scholar
Hoare CA. The trypanosomes of mammals: a zoological monograph. Oxford: Blackwell Scientific Publications; 1972. p. 749.
Google Scholar
Milocco C, Kamyingkird K, Desquesnes M, Jittapalapong S, Herbreteau V, Chaval Y, et al. Molecular demonstration of Trypanosoma evansi and Trypanosoma lewisi DNA in wild rodents from Cambodia, Lao PDR and Thailand. Transbound Emerg Dis. 2013;60:17–26.
Article
CAS
Google Scholar
Shi Y, Lai D, Liu D, Du L, Li Y, Fu X, et al. Morphological and molecular characteristics of a Trypanosoma sp. from triatomines (Triatoma rubrofasciata) in China. Parasit Vectors. 2024;17:214.
Article
CAS
Google Scholar
Buscher P, Gilleman Q, Lejon V. Rapid diagnostic test for sleeping sickness. N Engl J Med. 2013;368:1069–70.
Article
CAS
Google Scholar
Buscher P, Mertens P, Leclipteux T, Gilleman Q, Jacquet D, Mumba-Ngoyi D, et al. Sensitivity and specificity of hat sero-k-set, a rapid diagnostic test for serodiagnosis of sleeping sickness caused by Trypanosoma brucei gambiense: a case-control study. Lancet Glob Health. 2014;2:e359–63.
Article
Google Scholar
Bern C. Chagas’ disease. N Engl J Med. 2015;373:456–66.
Article
CAS
Google Scholar
Kumar R, Gupta S, Bhutia WD, Vaid RK, Kumar S. Atypical human trypanosomosis: potentially emerging disease with lack of understanding. Zoonoses Public Health. 2022;69:259–76.
Article
CAS
Google Scholar
Powar RM, Shegokar VR, Joshi PP, Dani VS, Tankhiwale NS, Truc P, et al. A rare case of human trypanosomiasis caused by Trypanosoma evansi. Indian J Med Microbiol. 2006;24:72–4.
Article
CAS
Google Scholar
Kaur R, Gupta VK, Dhariwal AC, Jain DC, Shiv L. A rare case of trypanosomiasis in a two month old infant in Mumbai, India. J Commun Dis. 2007;39:71–4.
Google Scholar
Sarataphan N, Vongpakorn M, Nuansrichay B, Autarkool N, Keowkarnkah T, Rodtian P, et al. Diagnosis of a Trypanosoma lewisi-like (herpetosoma) infection in a sick infant from Thailand. J Med Microbiol. 2007;56:1118–21.
Article
CAS
Google Scholar
Truc P, Jamonneau V, N’Guessan P, N’Dri L, Diallo PB, Cuny G. Trypanosoma brucei spp. and T. congolense: mixed human infection in Cote d’Ivoire. Trans R Soc Trop Med Hyg. 1998;92:537–8.
Article
CAS
Google Scholar
Lun ZR, Reid SA, Lai DH, Li FJ. Atypical human trypanosomiasis: a neglected disease or just an unlucky accident? Trend Parasitol. 2009;25:107–8.
Article
Google Scholar
Hamilton PB, Lewis MD, Cruickshank C, Gaunt MW, Yeo M, Llewellyn MS, et al. Identification and lineage genotyping of south American trypanosomes using fluorescent fragment length barcoding. Infect Genet Evol. 2011;11:44–51.
Article
CAS
Google Scholar
Maeda FY, Cortez C, Alves RM, Yoshida N. Mammalian cell invasion by closely related Trypanosoma species T. dionisii and T. cruzi. Acta Trop. 2012;121:141–7.
Article
Google Scholar
Oliveira MP, Ramos TC, Pinheiro AM, Bertini S, Takahashi HK, Straus AH, et al. Tridimensional ultrastructure and glycolipid pattern studies of Trypanosoma dionisii. Acta Trop. 2013;128:548–56.
Article
CAS
Google Scholar
Dario MA, Rodrigues MS, Barros JH, Xavier SC, D’Andrea PS, Roque AL, et al. Ecological scenario and Trypanosoma cruzi DTU characterization of a fatal acute chagas disease case transmitted orally (Espirito Santo state, Brazil). Parasit Vectors. 2016;9:477.
Article
Google Scholar
Oliveira MP, Cortez M, Maeda FY, Fernandes MC, Haapalainen EF, Yoshida N, et al. Unique behavior of Trypanosoma dionisii interacting with mammalian cells: invasion, intracellular growth, and nuclear localization. Acta Trop. 2009;110:65–74.
Article
CAS
Google Scholar
Gardner RA, Molyneux DH. Schizotrypanum in British bats. Parasitology. 1988;97:43–50.
Article
Google Scholar
Barros J, Roque ALR, Xavier S, Nascimento KCS, Toma HK, Madeira MF. Biological and genetic heterogeneity in Trypanosoma dionisii isolates from hematophagous and insectivorous bats. Pathogens. 2020;9:736.
Article
Google Scholar
Santos FM, Barreto WTG, de Macedo GC, Barros J, Xavier S, Garcia CM, et al. The reservoir system for Trypanosoma (Kinetoplastida, Trypanosomatidae) species in large Neotropical wetland. Acta Trop. 2019;199: 105098.
Article
CAS
Google Scholar
Xu N, Zhang X, Liu H, Xu Y, Lu H, Zhao L, et al. Clinical and epidemiological investigation of human infection with zoonotic parasite Trypanosoma dionisii in China. J Infect. 2024;89: 106290.
Article
CAS
Google Scholar
J Z M. Research on grassroots grid social governanceproblems and countermeasures in guangraocounty, Dongying city. Jinan City, Shandong Province: Shandong University of Finance and Economics. 2023.
Wang LJ, Han HJ, Zhao M, Liu JW, Luo LM, Wen HL, et al. Trypanosoma dionisii in insectivorous bats from northern China. Acta Trop. 2019;193:124–8.
Article
Google Scholar
Whitman JD, Bulman CA, Gunderson EL, Irish AM, Townsend RL, Stramer SL, et al. Chagas disease serological test performance in U.S. Blood donor specimens. J Clin Microbiol. 2019;57:e01217-e1219.
Article
CAS
Google Scholar
Suescun-Carrero SH, Salamanca-Cardozo LP, Pinazo MJ, Armadans-Gil L. Sensitivity and specificity of two rapid tests for the diagnosis of infection by Trypanosoma cruzi in a Colombian population. PLoS Negl Trop Dis. 2021;15: e0009483.
Article
CAS
Google Scholar
Noyes HA, Stevens JR, Teixeira M, Phelan J, Holz P. A nested PCR for the ssrrna gene detects Trypanosoma binneyi in the platypus and Trypanosoma sp. in wombats and Kangaroos in Australia. Int J Parasitol. 1999;29:331–9.
Article
CAS
Google Scholar
Smith SA, Beaulieu JM, Donoghue MJ. Mega-phylogeny approach for comparative biology: an alternative to supertree and supermatrix approaches. BMC Evol Biol. 2009;9:37.
Article
Google Scholar
Nishimaki T, Sato K. An extension of the kimura two-parameter model to the natural evolutionary process. J Mol Evol. 2019;87:60–7.
Article
CAS
Google Scholar
Mafie E, Rupa FH, Takano A, Suzuki K, Maeda K, Sato H. First record of Trypanosoma dionisii of the T. cruzi clade from the eastern bent-winged bat (Miniopterus fuliginosus) in the far east. Parasitol Res. 2018;117:673–80.
Cai Y, Wang X, Zhang N, Li J, Gong P, He B, et al. First report of the prevalence and genotype of Trypanosoma spp. In bats in Yunnan province southwestern China. Acta Trop. 2019;198:105105.
Article
CAS
Google Scholar
Linhart P, Bandouchova H, Zukal J, Votypka J, Balaz V, Heger T, et al. Blood parasites and health status of hibernating and non-hibernating noctule bats (Nyctalus noctula). Microorganisms. 2022;10:1028.
Article
CAS
Google Scholar
Austen JM, Van Kampen E, Egan SL, O’Dea MA, Jackson B, Ryan UM, et al. First report of Trypanosoma dionisii (Trypanosomatidae) identified in Australia. Parasitology. 2020;147:1801–9.
Article
CAS
Google Scholar
Juarez-Gabriel J, Alegria-Sanchez D, Yanez-Aguirre D, Grostieta E, Alvarez-Castillo L, Torres-Castro M, et al. Unraveling the diversity of Trypanosoma species from central Mexico: molecular confirmation on the presence of Trypanosoma dionisii and novel neobat linages. Acta Trop. 2024;251: 107113.
Article
CAS
Google Scholar
Berbigier AP, Barros J, Pontes ES, Lisboa CV, Gentile R, Xavier S, et al. Trypanosomatid richness in wild and synanthropic small mammals from a biological station in Rio De Janeiro, Brazil. Pathogens. 2021;10:1442.
Article
Google Scholar
Ossa G, Johnson JS, Puisto AIE, Rinne V, Saaksjarvi IE, Waag A, et al. The klingon batbugs: morphological adaptations in the primitive bat bugs, bucimex chilensis and primicimex cavernis, including updated phylogeny of Cimicidae. Ecol Evol. 2019;9:1736–49.
Article
Google Scholar
Najera-Cortazar LA, Keen A, Kitching T, Stokes D, Goodman SJ. Phylogenetic analyses reveal bat communities in northwestern mexico harbor a high diversity of novel cryptic ectoparasite species. Ecol Evol. 2023;13: e9645.
Article
Google Scholar
Malysheva MN, Ganyukova AI, Frolov AO, Chistyakov DV, Kostygov AY. The mite steatonyssus periblepharus is a novel potential vector of the bat parasite Trypanosoma dionisii. Microorganisms. 2023;11:2906.
Article
CAS
Google Scholar
Van Dyken M, Bolling BG, Moore CG, Blair CD, Beaty BJ, Black WCT, et al. Molecular evidence for trypanosomatids in culex mosquitoes collected during a west Nile virus survey. Int J Parasitol. 2006;36:1015–23.
Article
Google Scholar
Krafsur ES. Tsetse flies: genetics, evolution, and role as vectors. Infect Genet Evol. 2009;9:124–41.
Article
CAS
Google Scholar
Salazar R, Castillo-Neyra R, Tustin AW, Borrini-Mayori K, Naquira C, Levy MZ. Bed bugs (Cimex lectularius) as vectors of Trypanosoma cruzi. Am J Trop Med Hyg. 2015;92:331–5.
Article
Google Scholar
Giordani F, Morrison LJ, Rowan TG, De Koning HP, Barrett MP. The animal trypanosomiases and their chemotherapy: a review. Parasitology. 2016;143:1862–89.
Article
Google Scholar
Marotta CR, Dos Santos PN, Cordeiro MD, Da SBJH, Bell-Sakyi L, Fonseca AH. Trypanosoma amblyommi sp. Nov. (protozoa: Kinetoplastida) isolated from Amblyomma brasiliense (acari: Ixodidae) ticks in Rio De Janeiro. Brazil. Parasitol Open. 2018;4:e2.
Article
Google Scholar
Szentivanyi T, Heintz AC, Markotter W, Wassef J, Christe P, Glaizot O. Vector-borne protozoan and bacterial pathogen occurrence and diversity in ectoparasites of the egyptian rousette bat. Med Vet Entomol. 2023;37:189–94.
Article
CAS
Google Scholar
Hieu HV, Do LT, Pita S, Ha H, Khoa PT, Tuan PA, et al. Biological attributes of the kissing bug Triatoma rubrofasciata from vietnam. Parasit Vectors. 2019;12:585.
Article
CAS
Google Scholar
Kazim AR, Low VL, Houssaini J, Tappe D, Heo CC. Tick-associated Trypanosoma species (Apicomplexa: Kinetoplastida) from cattle ticks (Acari: Ixodidae) in peninsular Malaysia. Acta Trop. 2024;259: 107383.
Article
CAS
Google Scholar
Krige AS, Thompson RCA, Clode PL. ‘Hang on a Tick’- are ticks really the vectors for Australian Trypanosomes? Trend Parasitol. 2019;35:596–606.
Article
Google Scholar
Jansen AM, Xavier SC, Roque AL. The multiple and complex and changeable scenarios of the Trypanosoma cruzi transmission cycle in the sylvatic environment. Acta Trop. 2015;151:1–15.
Article
Google Scholar
Monje-Rumi MM, Brandan CP, Ragone PG, Tomasini N, Lauthier JJ, Alberti D’Amato AM, et al. Trypanosoma cruzi diversity in the Gran Chaco: mixed infections and differential host distribution of TcV and TcVI. Infect Genet Evol. 2015;29:53–9.
The housing market was flat in June as signs emerge that the UK jobs market may be “softening”, one of Britain’s biggest mortgage lenders has said.
The average price for a house in the UK was £296,665 in June, according to Halifax, compared with £296,782 in May. It comes after a slight drop of 0.3% in May, although the average house price was still about 2.5% higher in June compared with a year earlier.
Amanda Bryden, the head of mortgages at Halifax, said the market was resilient thanks to wage growth and stable interest rates. However, she added that buyers and homeowners still had to dig deep.
“Affordability is still stretched, particularly for those coming to the end of fixed-rate deals,” she said. “The economic backdrop also remains uncertain; while inflation has eased, it’s still above target, and there are signs the job market may be softening.”
The unemployment rate in the UK hit its highest level in four years in the first three months of this year, at 4.5%. That was up 0.2% on the previous quarter, according to official figures.
However, the housing market could be supported by a lower cost of borrowing, with two more interest rate cuts expected this year, Bryden added. With the average rate on new mortgages now at its lowest since 2023, Halifax anticipates “modest” house price growth for the rest of the year.
The number of first-time buyers in the market has also fallen back to its normal level before the changes to stamp duty, Halifax said. Temporary cuts to the tax in England and Northern Ireland expired in April, adding thousands of pounds to the cost of many property transactions.
skip past newsletter promotion
after newsletter promotion
Anthony Codling, of the broker RBC Capital Markets, said the end of the stamp duty holiday had followed its “usual playbook: a rush of transactions as the deadline approaches, a short lull, then back to business as usual”.
“In our view stamp duty holidays pull housing transactions forward rather than creating more transactions overall,” he said. “The return of first-time buyers is a positive sign, a key indicator of the health of the housing market and with wages still rising, and mortgage rates expected to fall, the housing market is in good health as we approach the summer holidays.”
Last week, rival lender Nationwide reported that house prices dropped by the most in two years in June. It calculated that the average price of a home dropped by 0.8% to £271,619, after a 0.4% gain in May.
However, analysts at the building society also said it expected activity to “pick up as the summer progresses, despite ongoing economic uncertainties in the global economy, since underlying conditions for potential homebuyers in the UK remain supportive”.
